1. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China
    Dao-guang Chen et al, 2021, Infectious Agents and Cancer CrossRef
  2. Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis
    Marine Lemaitre et al, 2020, Journal of Infection CrossRef
  3. Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma
    Chieh-Lung Cheng et al, 2022, Journal of Cancer Research and Clinical Oncology CrossRef
  4. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis
    Hong Li et al, 2015, Clinics and Research in Hepatology and Gastroenterology CrossRef
  5. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B‐cell lymphoma
    Xiang Zhou et al, 2019, European Journal of Haematology CrossRef
  6. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B‐cell lymphoma in Taiwan – a population‐based study
    Huai‐Hsuan Huang et al, 2021, British Journal of Haematology CrossRef
  7. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin
    Lijuan Deng et al, 2015, Oncotarget CrossRef
  8. Inferior survival and frequent hepatic dysfunction in non-Hodgkin’s lymphoma patients with HBV infection: a systematic review and meta-analysis
    Min-Yue Zhang et al, 2022, Hematology CrossRef
  9. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
    Jiangfang Feng et al, 2024, Hematological Oncology CrossRef

  10. Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma


    Xindan Kang et al, 2020, Cancer Management and Research CrossRef
  11. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Chieh-Lung Cheng et al, 2020, The Oncologist CrossRef
  12. HBx induces chemoresistance in diffuse large B cell lymphoma by inhibiting intrinsic apoptosis via the NF-κB/XIAP pathway
    Zhumei Zhan et al, 2024, Molecular Therapy - Nucleic Acids CrossRef
  13. Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
    Wei Guo et al, 2015, PLOS ONE CrossRef